{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:18:52Z","timestamp":1792289932305,"version":"4.4.0"},"reference-count":17,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX\u00ae (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN\u00ae (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2\u201313) and 21 (6\u201368) months, respectively. From baseline to first injection, 44 patients (73%) had &gt;50% reduction in frequency of migraine episodes, 29 patients (48%) showed &gt;50% reduction in number of headache days, and 28 patients (46%) had a &gt;50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN\u00ae thus seems to represent an effective and sustained prophylactic treatment of chronic migraine.<\/jats:p>","DOI":"10.3390\/toxins10060221","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T03:02:50Z","timestamp":1527822170000},"page":"221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN\u00ae) Botulinum Toxin in Chronic Refractory Migraine"],"prefix":"10.3390","volume":"10","author":[{"given":"Ioana","family":"Ion","sequence":"first","affiliation":[{"name":"Department of Neurology, Nimes University Hospital, 30900 Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Renard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nimes University Hospital, 30900 Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Le Floch","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nimes University Hospital, 30900 Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"De Verdal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nimes University Hospital, 30900 Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Bouly","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nimes University Hospital, 30900 Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wacongne","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nimes University Hospital, 30900 Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lozza","sequence":"additional","affiliation":[{"name":"Neurological Institute, Foundation Casimiro Mondino, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Castelnovo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nimes University Hospital, 30900 Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","article-title":"The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide","volume":"27","author":"Stovner","year":"2007","journal-title":"Cephalalgia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s11606-013-2433-1","article-title":"Preventive Pharmacologic Treatments for Episodic Migraine in Adults","volume":"28","author":"Shamliyan","year":"2013","journal-title":"J. Gen. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jackson, J.L., Cogbill, E., Santana-Davila, R., Eldredge, C., Collier, W., Gradall, A., Sehgal, N., and Kuester, J. (2015). A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130733"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline","volume":"331","author":"Silberstein","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/00207454.2016.1196687","article-title":"Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: A prospective pilot study","volume":"127","author":"Zhang","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1111\/bph.12763","article-title":"Therapeutic use of botulinum toxin in migraine: Mechanisms of action: Botulinum toxins as a prophylaxis for migraine","volume":"171","author":"Ramachandran","year":"2014","journal-title":"Br. J. Pharmacol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/toxins7093818","article-title":"Botulinum Toxin Type A as a Therapeutic Agent against Headache and Related Disorders","volume":"7","author":"Luvisetto","year":"2015","journal-title":"Toxins"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1592\/phco.29.7.784","article-title":"Efficacy of Botulinum Toxin Type A for the Prophylaxis of Episodic Migraine Headaches: A Meta-analysis of Randomized, Double-Blind, Placebo-Controlled Trials","volume":"29","author":"Shuhendler","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1468-2982.2006.01114.x","article-title":"Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Tension-Type Headache: A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study","volume":"26","author":"Silberstein","year":"2006","journal-title":"Cephalalgia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1526-4610.2011.02022.x","article-title":"Insights into the Mechanism of OnabotulinumtoxinA in Chronic Migraine: November\/December 2011","volume":"51","author":"Durham","year":"2011","journal-title":"Headache"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Frevert, J., and Dressler, D. (2010). Complexing proteins in botulinum toxin type A drugs: A help or a hindrance?. Biol. Targets Ther., 325.","DOI":"10.2147\/BTT.S14902"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.clinthera.2015.05.509","article-title":"IncobotulinumtoxinA for Migraine: A Retrospective Case Series","volume":"37","author":"Kazerooni","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s10194-017-0781-7","article-title":"OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: An observational, open label, real-life cohort study","volume":"18","author":"Ranoux","year":"2017","journal-title":"J. Headache Pain"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 33, 629\u2013808.","DOI":"10.1177\/0333102413485658"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/6\/221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:06:45Z","timestamp":1760195205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/6\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["toxins10060221"],"URL":"https:\/\/doi.org\/10.3390\/toxins10060221","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}